- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data - - Phase 1 results following a single dose of 10 mg/kg of PGN-EDO51 in healthy volunteers
